NTV Asset Management LLC Sells 150 Shares of Amgen Inc. (NASDAQ:AMGN)

NTV Asset Management LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,739 shares of the medical research company’s stock after selling 150 shares during the quarter. NTV Asset Management LLC’s holdings in Amgen were worth $2,799,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of AMGN. Capital Performance Advisors LLP bought a new position in shares of Amgen during the 3rd quarter worth $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the 3rd quarter worth $29,000. Heck Capital Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth $36,000. Livelsberger Financial Advisory bought a new position in shares of Amgen during the 3rd quarter worth $56,000. Finally, Kennebec Savings Bank bought a new position in shares of Amgen during the 3rd quarter worth $57,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Amgen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners dropped their price target on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Finally, Piper Sandler upped their price objective on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.09.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,405 shares of company stock worth $10,410,596 over the last three months. 0.69% of the stock is currently owned by insiders.

Amgen Trading Down 2.0 %

Amgen stock opened at $291.16 on Monday. The stock has a 50-day moving average of $274.12 and a two-hundred day moving average of $301.63. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.96 and a current ratio of 1.26. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock has a market cap of $156.51 billion, a PE ratio of 38.56, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts anticipate that Amgen Inc. will post 20.59 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.27%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 119.21%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.